Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Futura Medical ( (GB:FUM) ) has issued an update.
Futura Medical has announced that its revenue for the year ending December 2025 is expected to be significantly below expectations due to slower-than-anticipated sales of its lead product, Eroxon, particularly in the USA. The delay in the expected US patent milestone payment has further impacted revenue forecasts. As a result, the company is exploring options to extend its cash runway, including restructuring and potential strategic partnerships or asset sales. The ongoing strategic review aims to optimize the company’s sales and marketing strategies and explore alternative partnering and distribution arrangements for its products.
The most recent analyst rating on (GB:FUM) stock is a Buy with a £140.00 price target. To see the full list of analyst forecasts on Futura Medical stock, see the GB:FUM Stock Forecast page.
More about Futura Medical
Futura Medical plc is a consumer healthcare company specializing in the development and commercialization of innovative sexual health products. Their lead product, Eroxon, is a clinically proven topical gel treatment for erectile dysfunction (ED), which is available over the counter and helps men achieve an erection within ten minutes. The company also has new products in development, such as WSD4000 for women’s sexual dysfunction. Futura has distribution partners in major markets including the USA and Europe.
Average Trading Volume: 668,999
Technical Sentiment Signal: Sell
Current Market Cap: £26.55M
For detailed information about FUM stock, go to TipRanks’ Stock Analysis page.